The Role of AMPK/mTOR Modulators in the Therapy of Acute Myeloid Leukemia

Author(s): Dora Visnjic*, Vilma Dembitz, Hrvoje Lalic .

Journal Name: Current Medicinal Chemistry

Volume 26 , Issue 12 , 2019

Become EABM
Become Reviewer


Differentiation therapy of acute promyelocytic leukemia with all-trans retinoic acid represents the most successful pharmacological therapy of acute myeloid leukemia (AML). Numerous studies demonstrate that drugs that inhibit mechanistic target of rapamycin (mTOR) and activate AMP-kinase (AMPK) have beneficial effects in promoting differentiation and blocking proliferation of AML. Most of these drugs are already in use for other purposes; rapalogs as immunosuppressants, biguanides as oral antidiabetics, and 5-amino-4-imidazolecarboxamide ribonucleoside (AICAr, acadesine) as an exercise mimetic. Although most of these pharmacological modulators have been widely used for decades, their mechanism of action is only partially understood. In this review, we summarize the role of AMPK and mTOR in hematological malignancies and discuss the possible role of pharmacological modulators in proliferation and differentiation of leukemia cells.

Keywords: AML, AMPK, mTOR, rapamycin, metformin, AICAR, differentiation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [2208 - 2229]
Pages: 22
DOI: 10.2174/0929867325666180117105522
Price: $58

Article Metrics

PDF: 22